Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer
- 4 April 2011
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (9) , 1336-1342
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease ProgressionJournal of Clinical Oncology, 2010
- Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Treatment of Small Cell Lung Cancer in the ElderlyThe Oncologist, 2005
- Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug AdministrationJournal of Clinical Oncology, 2004
- Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104Journal of Clinical Oncology, 2002
- Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Chemotherapy in the Elderly: Pharmacologic ConsiderationsCancer Control, 2000
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999
- Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and EtoposideNew England Journal of Medicine, 1999